Should Healthy People Take Metformin for Longevity?
Metformin has become one of the best-known drugs in the longevity conversation.
It has been used for decades to treat type 2 diabetes. Research has also linked metformin use with lower rates of several diseases that become more common with age, and some studies have reported lower mortality among people taking it.
This has led to a much bigger question:
Should healthy people take metformin to help them live longer?
At present, the evidence does not support such a broad recommendation.
Why Is Metformin So Interesting for Longevity?
The interest is understandable.
Metformin affects glucose metabolism and insulin sensitivity — processes closely connected with metabolic health. Metabolic disease, in turn, increases the risk of cardiovascular disease and many other conditions that can shorten healthy life.
There are also encouraging human observations.
In people with type 2 diabetes, metformin use has been associated with lower all-cause mortality and lower incidence of cardiovascular disease and dementia.
These are important outcomes. They suggest that metformin may contribute indirectly to healthier aging in people who already have metabolic disease.
But this does not tell us what happens when a healthy person takes metformin specifically to slow aging.
What About People Without Diabetes?
This is where the evidence becomes much less certain.
Metformin can reduce the risk of developing type 2 diabetes in some people who are already at high metabolic risk. In that situation, preventing or delaying diabetes may help preserve health over time.
That is very different from giving metformin to a metabolically healthy person solely because aging will eventually increase their risk of disease.
We currently do not have convincing human evidence showing that metformin makes healthy people live longer.
Nor has it been established that taking metformin slows the fundamental biological processes of aging in healthy humans.
What About Heart Disease and Cancer?
These are among the reasons metformin attracted so much attention.
Observational research has linked metformin with lower cardiovascular and cancer mortality. More recent research in people with type 2 diabetes has also found associations with lower cardiovascular disease and dementia.
But observational research has an important limitation.
People taking metformin may differ from people receiving other treatments in many ways — including the severity of their diabetes, other medications and overall health. Researchers can adjust for some of these differences, but not necessarily all of them.
This makes the findings important, but it prevents us from concluding that metformin itself caused people to live longer.
Evidence concerning cancer is particularly mixed and varies between cancer types.
Could Metformin Still Support Healthy Aging?
Yes — particularly in the right patient.
A treatment does not have to directly slow biological aging to contribute to a longer healthspan.
If metformin helps a person at high metabolic risk prevent or delay type 2 diabetes, that may help protect future health. In someone who already has type 2 diabetes, better long-term outcomes could also translate into more years lived without major complications.
This is an important part of longevity medicine: preventing disease can be one route to healthier aging.
But the expected benefit depends on the person taking the drug.
Metformin used for an established metabolic indication is very different from metformin prescribed to a healthy person purely as an anti-aging intervention.
So Is Metformin a Longevity Drug?
It is more accurate to call metformin a promising longevity research candidate than a proven anti-aging treatment for healthy people.
Its long clinical history, metabolic effects and associations with important health outcomes make it scientifically interesting.
But the evidence has boundaries.
We have meaningful evidence for specific metabolic benefits and encouraging healthspan-related observations in people with type 2 diabetes.
We do not yet have evidence showing that routinely giving metformin to healthy people extends lifespan or reliably slows biological aging.
That distinction matters when moving from an interesting longevity hypothesis to a treatment decision.
